RecruitingNCT06794268

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Studying Follicular lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention
Lisocabtagene maraleucel(biological)
Enrollment
300 target
Eligibility
18 years · All sexes
Timeline
2025 – 2044

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06794268 on ClinicalTrials.gov

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Follicular lymphoma →

← Back to all trials